Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

419 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Least among equals.
Kuritzkes DR, Hakim JG, Sanne I. Kuritzkes DR, et al. Clin Infect Dis. 2012 Mar;54(6):876-7. doi: 10.1093/cid/cir1048. Clin Infect Dis. 2012. PMID: 22357810 Free PMC article. No abstract available.
Antiretroviral therapies in women after single-dose nevirapine exposure.
Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A, Hosseinipour MC, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, Shaffer D, Kanyama C, Wools-Kaloustian K, Salata RA, Hogg E, Alston-Smith B, Walawander A, Purcelle-Smith E, Eshleman S, Rooney J, Rahim S, Mellors JW, Schooley RT, Currier JS; OCTANE A5208 Study Team. Lockman S, et al. N Engl J Med. 2010 Oct 14;363(16):1499-509. doi: 10.1056/NEJMoa0906626. N Engl J Med. 2010. PMID: 20942666 Free PMC article. Clinical Trial.
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.
Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, Chipato T, Asmelash A, Rassool M, Kimaiyo S, Shaffer D, Hosseinipour M, Mohapi L, Ssali F, Chibowa M, Amod F, Halvas E, Hogg E, Alston-Smith B, Smith L, Schooley R, Mellors J, Currier J; OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG A5208/OCTANE Study Team. Lockman S, et al. PLoS Med. 2012;9(6):e1001236. doi: 10.1371/journal.pmed.1001236. Epub 2012 Jun 12. PLoS Med. 2012. PMID: 22719231 Free PMC article. Clinical Trial.
Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.
Boltz VF, Bao Y, Lockman S, Halvas EK, Kearney MF, McIntyre JA, Schooley RT, Hughes MD, Coffin JM, Mellors JW; OCTANE/A5208 Team. Boltz VF, et al. J Infect Dis. 2014 Mar 1;209(5):703-10. doi: 10.1093/infdis/jit635. Epub 2014 Jan 16. J Infect Dis. 2014. PMID: 24443547 Free PMC article. Clinical Trial.
HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians.
Lubinski C, Aberg J, Bardeguez AD, Elion R, Emmanuel P, Kuritzkes D, Saag M, Squires KE, Weddle A, Rainey J, Zerehi MR, Ralston JF, Fleming DA, Bronson D, Cooke M, Cutler C, Ejnes Y, Gluckman R, Liebow M, Musana K, Mayer ME, Purtle MW, Reynolds PP, Viswanathan L, Weiss KB, Yehia B. Lubinski C, et al. Clin Infect Dis. 2009 May 15;48(10):1335-44. doi: 10.1086/598169. Clin Infect Dis. 2009. PMID: 19385087 Free article. No abstract available.
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.
Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, Lederman M, Acosta EP, Campbell T, Feinberg J, Flexner C, Mellors JW, Kuritzkes DR; AIDS Clinical Trials Group A5248 Team. Andrade A, et al. Among authors: kuritzkes dr. J Infect Dis. 2013 Sep;208(6):884-91. doi: 10.1093/infdis/jit272. Epub 2013 Jun 24. J Infect Dis. 2013. PMID: 23801609 Free PMC article. Clinical Trial.
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS; AIDS Clinical Trials Group (ACTG) A5257 Team. Ofotokun I, et al. Among authors: kuritzkes dr. Clin Infect Dis. 2015 Jun 15;60(12):1842-51. doi: 10.1093/cid/civ193. Epub 2015 Mar 12. Clin Infect Dis. 2015. PMID: 25767256 Free PMC article. Clinical Trial.
Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
Skowron G, Kuritzkes DR, Thompson MA, Squires KE, Goodwin SD, Dusak BA, Tolson JM, Stevens M, Yuen GJ, Rooney JF; Intercompany Collaboration for AIDS Drug Development Protocol 604 Team. Skowron G, et al. Among authors: kuritzkes dr. J Infect Dis. 2002 Oct 1;186(7):1028-33. doi: 10.1086/343740. Epub 2002 Sep 13. J Infect Dis. 2002. PMID: 12232846 Clinical Trial.
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.
Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD. Hirsch MS, et al. Among authors: kuritzkes dr. Clin Infect Dis. 2003 Jul 1;37(1):113-28. doi: 10.1086/375597. Epub 2003 Jun 23. Clin Infect Dis. 2003. PMID: 12830416
419 results